Majid Davari1, Azita Nabizadeh1, Maliheh Kadivar2, Akbar Abdollahi Asl1, Peymaneh Sarkheil3. 1. 1Department of Pharmacoeconomics and Pharmaceutical Administration, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. 2. 2Children's Hospital Medical Center, Tehran University of Medical Sciences, Tehran, Iran. 3. 3Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Abstract
INTRODUCTION: Gaucher disease (GD) is an inherited recessive enzyme deficiency with a multisystem condition. The Iranian government covers the therapeutic expenditure of GD patients as it is not affordable for the patients. The aim of this study is to identify the main components of the cost of care in Gaucher patients (GPs) in Iran. METHODS: The Gaucher patients were identified from the Iran Food and Drug Administration (IFDA) national registry database. The direct medical costs, including medication, diagnostic services, and physician visits were considered. The prices of therapeutic and diagnostic services were extracted from Iranian medical tariff book 2014-15. Iran Food and Drug Administration determined the cost of medications. RESULTS: 164 Gaucher patients have been registered in Iran. A valid and reliable diagnostic tests are not used to identify the type of GD. The average health care cost per annum was 20,758 USD per patient, which is higher than 4 GDP per capita in Iran. Medication cost constitutes 95.2% of the total cost. The average cost of each GP was $1,473,818 in his/her total life. CONCLUSION: GD is amongst the high-cost diseases and should be managed effectively. The application of oral medication for eligible GPs could improve allocative efficiency in GD management significantly. A sound, valid and reliable national clinical guideline could improve the efficiency of healthcare resources effectively. Selecting appropriate strategies for reducing the birth of a child with Gaucher, could support allocative efficiency of the limited resources effectively.
INTRODUCTION: Gaucher disease (GD) is an inherited recessive enzyme deficiency with a multisystem condition. The Iranian government covers the therapeutic expenditure of GD patients as it is not affordable for the patients. The aim of this study is to identify the main components of the cost of care in Gaucher patients (GPs) in Iran. METHODS: The Gaucher patients were identified from the Iran Food and Drug Administration (IFDA) national registry database. The direct medical costs, including medication, diagnostic services, and physician visits were considered. The prices of therapeutic and diagnostic services were extracted from Iranian medical tariff book 2014-15. Iran Food and Drug Administration determined the cost of medications. RESULTS: 164 Gaucher patients have been registered in Iran. A valid and reliable diagnostic tests are not used to identify the type of GD. The average health care cost per annum was 20,758 USD per patient, which is higher than 4 GDP per capita in Iran. Medication cost constitutes 95.2% of the total cost. The average cost of each GP was $1,473,818 in his/her total life. CONCLUSION: GD is amongst the high-cost diseases and should be managed effectively. The application of oral medication for eligible GPs could improve allocative efficiency in GD management significantly. A sound, valid and reliable national clinical guideline could improve the efficiency of healthcare resources effectively. Selecting appropriate strategies for reducing the birth of a child with Gaucher, could support allocative efficiency of the limited resources effectively.
Entities:
Keywords:
Cost; Gaucher disease; Health care; Iran; Resource utilization
Authors: N W Barton; R O Brady; J M Dambrosia; A M Di Bisceglie; S H Doppelt; S C Hill; H J Mankin; G J Murray; R I Parker; C E Argoff Journal: N Engl J Med Date: 1991-05-23 Impact factor: 91.245
Authors: Neal J Weinreb; Patrick Deegan; Katherine A Kacena; Pramod Mistry; Gregory M Pastores; Priscilla Velentgas; Stephan vom Dahl Journal: Am J Hematol Date: 2008-12 Impact factor: 10.047
Authors: Neal J Weinreb; Joel Charrow; Hans C Andersson; Paige Kaplan; Edwin H Kolodny; Pramod Mistry; Gregory Pastores; Barry E Rosenbloom; C Ronald Scott; Rebecca S Wappner; Ari Zimran Journal: Am J Med Date: 2002-08-01 Impact factor: 4.965
Authors: B C Krug; I V Schwartz; F Lopes de Oliveira; T Alegra; N L Campos Martins; L A Todeschini; P D Picon Journal: Public Health Genomics Date: 2009-05-04 Impact factor: 2.000
Authors: Neal J Weinreb; Mario C Aggio; Hans C Andersson; Generoso Andria; Joel Charrow; Joe T R Clarke; Anders Erikson; Pilar Giraldo; Jack Goldblatt; Carla Hollak; Hiroyuki Ida; Paige Kaplan; Edwin H Kolodny; Pramod Mistry; Gregory M Pastores; Ricardo Pires; Ainu Prakash-Cheng; Ainu Prakesh-Cheng; Barry E Rosenbloom; C Ronald Scott; Elisa Sobreira; Anna Tylki-Szymańska; Ashok Vellodi; Stephan vom Dahl; Rebecca S Wappner; Ari Zimran Journal: Semin Hematol Date: 2004-10 Impact factor: 3.851